Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Geron Corporation (GERN : NSDQ)

• Company Description    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Number of Employees: 229

• Price / Volume Information    Yesterday's Closing Price: $1.22 Daily Weekly Monthly 20 Day Moving Average: 7,311,079 shares Shares Outstanding: 638.02 (millions) Market Capitalization: $778.38 (millions) Beta: 0.57 52 Week High: $4.50 52 Week Low: $1.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.94% -5.84% 12 Week 6.09% -0.20% Year To Date -65.54% -69.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 919 EAST HILLSDALE BOULEVARD SUITE 250 - FOSTER CITY,CA 94404 USA ph: 650-473-7700 fax: 650-473-7750 investor@geron.com http://www.geron.com

• General Corporate Information    Officers JOHN A. SCARLETT - President; Chief Executive Officer and Chairman MICHELLE ROBERTSON - Executive Vice President; Finance; Chief Financi GAURAV AGGARWAL - Director DAWN C. BIR - Director V. BRYAN LAWLIS - Director Peer Information Geron Corporation (CORR.) Geron Corporation (RSPI) Geron Corporation (CGXP) Geron Corporation (BGEN) Geron Corporation (GTBP) Geron Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 374163103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 638.02 Most Recent Split Date: (:1) Beta: 0.57 Market Capitalization: $778.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.99 Price/Cash Flow: - Price / Sales: 4.73 EPS Growth vs. Year Ago Period: 80.00% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 5,459.64% vs. Previous Quarter: 23.82% ROE 09/30/25 - - 06/30/25 - -31.37 03/31/25 - -47.86 ROA 09/30/25 - - 06/30/25 - -16.01 03/31/25 - -26.78 Current Ratio 09/30/25 - - 06/30/25 - 7.87 03/31/25 - 7.87 Quick Ratio 09/30/25 - - 06/30/25 - 6.79 03/31/25 - 6.97 Operating Margin 09/30/25 - - 06/30/25 - -52.48 03/31/25 - -118.07 Net Margin 09/30/25 - - 06/30/25 - -53.52 03/31/25 - -119.54 Pre-Tax Margin 09/30/25 - - 06/30/25 - -53.52 03/31/25 - -119.54 Book Value 09/30/25 - - 06/30/25 - 0.41 03/31/25 - 0.42 Inventory Turnover 09/30/25 - - 06/30/25 - 0.08 03/31/25 - 0.08 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.46 03/31/25 - 0.44 Debt-to-Capital 09/30/25 - - 06/30/25 - 31.44 03/31/25 - 30.68

Powered by Zacks Investment Research ©